A
Ann Marie K. Crawford
Researcher at Eli Lilly and Company
Publications - 7
Citations - 622
Ann Marie K. Crawford is an academic researcher from Eli Lilly and Company. The author has contributed to research in topics: Olanzapine & Atypical antipsychotic. The author has an hindex of 6, co-authored 7 publications receiving 608 citations.
Papers
More filters
Journal ArticleDOI
Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial
Charles M. Beasley,Susan H. Hamilton,Ann Marie K. Crawford,Mary Anne Dellva,Gary D. Tollefson,Pierre V. Tran,Olivier Blin,Jean-Noel Beuzen +7 more
TL;DR: Although olanzapine was associated with some increase in prolactin concentrations, increases were transient, occurred less often, and were of lesser magnitude than those observed with haloperidol.
Journal ArticleDOI
The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations
TL;DR: Rapid adaptation was observed in the temporal course of prolactin elevations associated with olanzapine based on both the categorical analysis of treatment-emergent high values and the analyses of temporal change in mean concentrations.
Journal ArticleDOI
Olanzapine vs risperidone in the management of schizophrenia: a randomized double-blind trial in Australia and New Zealand
Oye Gureje,Wayne Sylvester Miles,Nicholas A Keks,David Grainger,Tim Lambert,John J. McGrath,Pierre Tran,Stanley V. Catts,Allen Fraser,H. Hustig,Scott W. Andersen,Ann Marie K. Crawford +11 more
TL;DR: Olanzapine has a superior risk:benefit profile compared to risperidone, and generic and disease-specific measures of quality of life, olanZapine-treated patients showed significant within-group improvement in most measures, and significant differences were observed in favor of olanzAPine in Quality of Life Scale (QLS) and Medical Outcomes Study Short Form 36-item instrument (SF-36) Role Functioning Limitations-Emotional subscale scores.
Journal ArticleDOI
Sex differences in clinical response to olanzapine compared with haloperidol
Jill M. Goldstein,Jill M. Goldstein,Lee S. Cohen,Nicholas J. Horton,Hang Lee,Scott W. Andersen,Mauricio Tohen,Mauricio Tohen,Ann Marie K. Crawford,Gary D. Tollefson +9 more
TL;DR: The sex differences in treatment response in olanzapine compared with haloperidol were dependent on chronicity and, in women, menopausal status, and premenopausal women had a significantly better treatment response than post menopausal women, regardless of treatment and chronicity.